New hope for rare cancer: ZG006 faces chemo in phase 3 showdown
NCT ID NCT07595913
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tests a new drug called ZG006 against standard chemotherapy in 240 adults with advanced neuroendocrine carcinoma, a rare cancer. Participants must have a specific marker (DLL3) and have already tried at least one prior treatment. The main goal is to see if ZG006 helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact
Conditions
Explore the condition pages connected to this study.